key: cord-0767146-l535h5d6
authors: O'Shea, Evelyn; Daly, Orna; Duggan, Cleona; Crowley, Maeve
title: Haemostatic Disarray Following COVID-19 Vaccine – a Case of Acquired Haemophila A
date: 2022-04-04
journal: Clin Appl Thromb Hemost
DOI: 10.1177/10760296221077981
sha: 2d036b380b62b487243c553437640ec0828b324e
doc_id: 767146
cord_uid: l535h5d6

nan

We read with interest Hafeez et al. discussion regarding concern about haemostatic adverse effects post vaccination. 1 Many haemostatic complications post COVID-19 vaccination have been reported including the syndrome of thrombocytopenia and thrombosis, as discussed by Hafeez et al. 1 In 2019, a new pandemic of coronavirus arose from China and quickly spread across the world. 2 It became a public health emergency. 2 Covid-19 infection usually begin with flu like symptoms however, about 10% of the symptomatic subjects may experience more severe course of the disease. 2 Vaccination became the cornerstone strategy in disease control and prevention of new and more severe cases of COVID-19 infection. 2 Here we would like to add to the haemostatic adverse events post vaccination reported by Hafeez et al. and report a case of Acquired Haemophilia A (AHA) one week following a Pfizer-BioNTech SARS-CoV-2 vaccine. AHA is a rare bleeding disorder (reported incidence; 1 per million/year) which results in spontaneous bleeding in people with no history of a bleeding disorder. 3 It is believed to be caused by autoantibodies directed against factor VIII (FVIII). 3 It most often seen in elderly patients and is often associated with autoimmune conditions or malignancies but many cases are idiopathic. 3 Here we discuss the rare occurrence of AHA post vaccination.

A 72-year-old gentleman developed forearm, arm and thigh bruising approximately one week after receiving the first dose of the Pfizer-BioNTech COVID-19 vaccine in April 2021. He attended his family doctor when the bruising extended, who referred him urgently to hospital. He had a history of successfully treated prostate carcinoma [prostate-specific antigen was 0.07 ng/ ml (normal range = 0-4 ng/ml)], non-insulin dependent diabetes and hypertension. His physical examination was unremarkable other than tongue swelling and extensive bruising. Bloods showed anaemia (haemoglobin: 79 g/L), a normal platelet count (288 × 10 9 /L, a prolonged activated partial thromboplastin time [ According to the European Centre for Disease Prevention and Control, 82.2% of adults have had at least one dose of a covid-19 vaccine and this rises to >94% in Ireland. 4 Pharmacovigilance is key when new medications or vaccines are introduced, especially to such a large proportion of the worlds' population as rare complications are likely to be seen. 5 Adverse Events Following Immunisation (AEFI) are reported in 53.7 per 100,000 COVID-19 vaccine doses administered. 6 The most common adverse events associated with the COVID-19 vaccine to date are allergic skin reactions and pain/redness/swelling at the injection site. Serious AEFI was reported in 2.8 per 100,000 doses of COVID-19 vaccine administered. 6 Four other cases of AHA following SARS-CoV-2 vaccination have been reported to date. [7] [8] [9] [10] Education about pharmacovigilance and trust in the system is key to limit vaccine scepticism. 5 The potential correlation between vaccinations and autoimmune disease has been postulated for a long time. 4 The pathogenetic mechanism and aetiology of this is still unclear. 5 It has been suggested that the mechanism of autoimmune disease development post vaccination is by molecular mimicry, by which viral or bacterial agents trigger an immune response against 1 Cork University Hospital, Cork, Ireland autoantigens. 5 Another hypothesis is; bystander activation, which involves the activation of quiescent auto-reactive T and B cells. 5 However, it is suggested that some people are more susceptible to developing these reactions due to a genetic predisposition to autoimmune diseases. 5 This hypothesis may explain the pathogenesis of AHA post SARS-CoV-2 vaccine.

COVID-19 infection rates are rising worldwide. 4 Booster doses are being administered and the vaccination programme is being expanded to children. 4 More haemostatic adverse events post vaccination are likely to be seen. Therefore, ongoing pharmacovigilance is required. 

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Our institution does not require ethical approval for reporting individual cases or case series.

The author(s) received no financial support for the research, authorship and/or publication of this article.

Verbal informed consent was obtained from a legally authorized representative(s) for anonymized patient information to be published in this article.

Trial registration was not required.

Evelyn O'Shea https://orcid.org/0000-0001-6797-5652

COVID-19 Vaccine-Associated thrombosis With thrombocytopenia syndrome (TTS): a systematic review and post Hoc analysis

A comprehensive review on rational and effective treatment strategies against an invisible enemy; SARS Cov-2 infection

A survey of 215 non-hemophilic patients with inhibitors to factor VIII

European Centre for Disease Prevention and Control COVID-19

Vaccine Tracker. 2021

Vaccination and autoimmune disease: what is the evidence?

COVID-19 Vaccines

A case report of acquired hemophilia following COVID-19 vaccine

Autoimmune-and complement-mediated hematologic condition recrudescence following SARS-CoV-2 vaccination

A case of acquired hemophilia A following SARS-CoV-2 infection

Autoimmunity after coronavirus disease 2019 (COVID-19) vaccine: a case of acquired hemophilia A